ERYTECH Pharma S.A. ERYP
$ 0.78
1.3%
Annual report 2022
added 11-23-2024
ERYTECH Pharma S.A. Balance Sheet 2011-2024 | ERYP
Annual Balance Sheet ERYTECH Pharma S.A.
2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | -28.5 M | -70.4 M | -133 M | -183 M | -34.8 M | -45.1 M | -36.2 M | -14.1 M | 3.07 M | - | |
Long Term Debt |
- | - | 14.4 M | 1.32 M | 1.24 M | 1.98 M | 2.66 M | 63 K | 436 K | 731 K | 6.4 M | - |
Long Term Debt Current |
775 K | 1.82 M | 1.61 M | 1.42 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | 24.5 M | 13.1 M | 1.59 M | 2.24 M | 2.98 M | 251 K | 525 K | 848 K | 6.69 M | - |
Total Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | - | 53.9 M | 33 M | 22.2 M | 13.8 M | 9.33 M | 5.87 M | 4.78 M | 4.36 M | 14.2 M | - |
Deferred Revenue |
- | - | 148 K | 61 K | 16 K | - | - | - | 368 K | 649 K | 943 K | - |
Retained Earnings |
- | - | -73.3 M | -62.7 M | -38.2 M | -33.5 M | -21.9 M | -15 M | -8.86 M | -8.14 M | -2.17 M | - |
Total Assets |
45.8 M | 66.8 M | 80.4 M | 119 M | 168 M | 195 M | 45 M | 53 M | 40.6 M | 17.9 M | 10.1 M | - |
Cash and Cash Equivalents |
38.8 M | 33.7 M | 44.4 M | 73.2 M | 134 M | 186 M | 37.6 M | - | - | - | - | - |
Book Value |
- | 66.8 M | 26.5 M | 85.6 M | 146 M | 181 M | 35.6 M | 47.1 M | 35.8 M | 13.6 M | -4.03 M | - |
Total Shareholders Equity |
- | - | 26.5 M | 85.6 M | 146 M | 181 M | 35.6 M | 47.1 M | - | - | - | - |
All numbers in EUR currency
Quarterly Balance Sheet ERYTECH Pharma S.A.
2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | 8.16 M | - | 8.82 M | - | 9.2 M | - | 10.5 M | - | 11.3 M | - | 8.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 23.9 M | - | 24 M | - | 24.5 M | - | 15.4 M | - | 13.1 M | - | 9.87 M | - | 1.59 M | - | - | - | 2.24 M | - | - | - | 2.98 M | - | - | - | 251 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
- | - | - | - | - | - | - | - | - | - | -35 M | - | -62.7 M | - | -29.3 M | - | -38.2 M | - | - | - | -33.5 M | - | - | - | -21.9 M | - | - | - | -15 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
- | - | - | - | 66.8 M | - | 83.8 M | - | 80.4 M | - | 89.1 M | - | 119 M | - | 146 M | - | 168 M | - | - | - | 195 M | - | - | - | 45 M | - | - | - | 53 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
- | - | - | - | 33.7 M | - | 46.3 M | - | 44.4 M | - | 45.4 M | - | 73.2 M | - | 94.5 M | - | 134 M | - | - | - | 186 M | - | - | - | 37.6 M | - | - | - | 45.6 M | - | - | - | 37 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
- | - | - | - | 66.8 M | - | 83.8 M | - | 80.4 M | - | 89.1 M | - | 119 M | - | 146 M | - | 168 M | - | - | - | 195 M | - | - | - | 45 M | - | - | - | 53 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
- | - | - | - | 22.8 M | - | 36.4 M | - | 26.5 M | - | 51.1 M | - | 85.6 M | - | 117 M | - | 146 M | - | 164 M | - | 181 M | - | - | - | 35.6 M | - | - | - | 47.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in EUR currency